Study of the absorption of Cefcapene pivoxil (cas 105889-45-0) in patients with infectious disease and soft stool or diarrhea

Add time:07/20/2019    Source:sciencedirect.com

Cefcapene pivoxil (cas 105889-45-0) hydrochloride (CFPN-PI), an ester cephem antibiotic, was orally given at a dose of 100mg three times daily in patients with infection and soft stool or diarrhea, and its absorption was determined using the recovery ratio of 12-h urine pooled after the initial administration as an index. The primary endpoint, the recovery ratio of 12-h urine pooled after oral administration, could be evaluated in six of the eight patients finally gathered, and the mean value was 30.1 ± 5.8%, which was not considered to differ from the mean value of 34.4 ± 5.5% obtained in six healthy adult volunteers in the previous phase I study. Clinical efficacy in the eight patients was rated as very effective, effective, and ineffective in two, five, and one patients, respectively, with an effective ratio of 87.5% (7/8). Neither adverse drug reactions nor abnormal laboratory data were observed in any patient. These results indicate that CFPNPI, at the routine oral dose, does not cause any problems in terms of absorption, efficacy, and safety when it is used in patients with infection and soft stool or diarrhea.

We also recommend Trading Suppliers and Manufacturers of Cefcapene pivoxil (cas 105889-45-0). Pls Click Website Link as below: cas 105889-45-0 suppliers

Prev:Determination of cefcapene acid by LC–MS and their application to a pharmacokinetic study in healthy Chinese volunteers
Next:The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro)